 | • レポートコード：MRC2-11QY05958 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は家族性大腸腺腫症治療のグローバル市場について調査・分析したレポートです。種類別（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別家族性大腸腺腫症治療の競争状況、市場シェア ・世界の家族性大腸腺腫症治療市場：種類別市場規模 2015年-2020年（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他） ・世界の家族性大腸腺腫症治療市場：種類別市場規模予測 2021年-2026年（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他） ・世界の家族性大腸腺腫症治療市場：用途別市場規模 2015年-2020年（クリニック、病院、その他） ・世界の家族性大腸腺腫症治療市場：用途別市場規模予測 2021年-2026年（クリニック、病院、その他） ・北米の家族性大腸腺腫症治療市場分析：米国、カナダ ・ヨーロッパの家族性大腸腺腫症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの家族性大腸腺腫症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の家族性大腸腺腫症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの家族性大腸腺腫症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Cancer Prevention Pharmaceuticals Inc、Marina Biotech Inc、Thetis Pharmaceuticals LLC ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Familial Adenomatous Polyposis Treatment Market
The global Familial Adenomatous Polyposis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Familial Adenomatous Polyposis Treatment Scope and Market Size
Familial Adenomatous Polyposis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Familial Adenomatous Polyposis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Familial Adenomatous Polyposis Treatment market is segmented into
Icosapent
Eflornithine Hydrochloride
Aspirin
CEQ-508
Others
Segment by Application, the Familial Adenomatous Polyposis Treatment market is segmented into
Clinic
Hospital
Others
Regional and Country-level Analysis
The Familial Adenomatous Polyposis Treatment market is analysed and market size information is provided by regions (countries).
The key regions covered in the Familial Adenomatous Polyposis Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Familial Adenomatous Polyposis Treatment Market Share Analysis
Familial Adenomatous Polyposis Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Familial Adenomatous Polyposis Treatment business, the date to enter into the Familial Adenomatous Polyposis Treatment market, Familial Adenomatous Polyposis Treatment product introduction, recent developments, etc.
The major vendors covered:
Cancer Prevention Pharmaceuticals Inc
Marina Biotech Inc
Thetis Pharmaceuticals LLC
…
1 Study Coverage
1.1 Familial Adenomatous Polyposis Treatment Product Introduction
1.2 Market Segments
1.3 Key Familial Adenomatous Polyposis Treatment Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Familial Adenomatous Polyposis Treatment Market Size Growth Rate by Type
1.4.2 Icosapent
1.4.3 Eflornithine Hydrochloride
1.4.4 Aspirin
1.4.5 CEQ-508
1.4.6 Others
1.5 Market by Application
1.5.1 Global Familial Adenomatous Polyposis Treatment Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Familial Adenomatous Polyposis Treatment Market Size, Estimates and Forecasts
2.1.1 Global Familial Adenomatous Polyposis Treatment Revenue 2015-2026
2.1.2 Global Familial Adenomatous Polyposis Treatment Sales 2015-2026
2.2 Global Familial Adenomatous Polyposis Treatment, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Familial Adenomatous Polyposis Treatment Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Familial Adenomatous Polyposis Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Familial Adenomatous Polyposis Treatment Competitor Landscape by Players
3.1 Familial Adenomatous Polyposis Treatment Sales by Manufacturers
3.1.1 Familial Adenomatous Polyposis Treatment Sales by Manufacturers (2015-2020)
3.1.2 Familial Adenomatous Polyposis Treatment Sales Market Share by Manufacturers (2015-2020)
3.2 Familial Adenomatous Polyposis Treatment Revenue by Manufacturers
3.2.1 Familial Adenomatous Polyposis Treatment Revenue by Manufacturers (2015-2020)
3.2.2 Familial Adenomatous Polyposis Treatment Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Familial Adenomatous Polyposis Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Familial Adenomatous Polyposis Treatment Revenue in 2019
3.2.5 Global Familial Adenomatous Polyposis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Familial Adenomatous Polyposis Treatment Price by Manufacturers
3.4 Familial Adenomatous Polyposis Treatment Manufacturing Base Distribution, Product Types
3.4.1 Familial Adenomatous Polyposis Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Familial Adenomatous Polyposis Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Familial Adenomatous Polyposis Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Familial Adenomatous Polyposis Treatment Market Size by Type (2015-2020)
4.1.1 Global Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020)
4.1.2 Global Familial Adenomatous Polyposis Treatment Revenue by Type (2015-2020)
4.1.3 Familial Adenomatous Polyposis Treatment Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Familial Adenomatous Polyposis Treatment Market Size Forecast by Type (2021-2026)
4.2.1 Global Familial Adenomatous Polyposis Treatment Sales Forecast by Type (2021-2026)
4.2.2 Global Familial Adenomatous Polyposis Treatment Revenue Forecast by Type (2021-2026)
4.2.3 Familial Adenomatous Polyposis Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Familial Adenomatous Polyposis Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Familial Adenomatous Polyposis Treatment Market Size by Application (2015-2020)
5.1.1 Global Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020)
5.1.2 Global Familial Adenomatous Polyposis Treatment Revenue by Application (2015-2020)
5.1.3 Familial Adenomatous Polyposis Treatment Price by Application (2015-2020)
5.2 Familial Adenomatous Polyposis Treatment Market Size Forecast by Application (2021-2026)
5.2.1 Global Familial Adenomatous Polyposis Treatment Sales Forecast by Application (2021-2026)
5.2.2 Global Familial Adenomatous Polyposis Treatment Revenue Forecast by Application (2021-2026)
5.2.3 Global Familial Adenomatous Polyposis Treatment Price Forecast by Application (2021-2026)
6 North America
6.1 North America Familial Adenomatous Polyposis Treatment by Country
6.1.1 North America Familial Adenomatous Polyposis Treatment Sales by Country
6.1.2 North America Familial Adenomatous Polyposis Treatment Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Familial Adenomatous Polyposis Treatment Market Facts & Figures by Type
6.3 North America Familial Adenomatous Polyposis Treatment Market Facts & Figures by Application
7 Europe
7.1 Europe Familial Adenomatous Polyposis Treatment by Country
7.1.1 Europe Familial Adenomatous Polyposis Treatment Sales by Country
7.1.2 Europe Familial Adenomatous Polyposis Treatment Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Familial Adenomatous Polyposis Treatment Market Facts & Figures by Type
7.3 Europe Familial Adenomatous Polyposis Treatment Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Familial Adenomatous Polyposis Treatment by Region
8.1.1 Asia Pacific Familial Adenomatous Polyposis Treatment Sales by Region
8.1.2 Asia Pacific Familial Adenomatous Polyposis Treatment Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Familial Adenomatous Polyposis Treatment Market Facts & Figures by Type
8.3 Asia Pacific Familial Adenomatous Polyposis Treatment Market Facts & Figures by Application
9 Latin America
9.1 Latin America Familial Adenomatous Polyposis Treatment by Country
9.1.1 Latin America Familial Adenomatous Polyposis Treatment Sales by Country
9.1.2 Latin America Familial Adenomatous Polyposis Treatment Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Familial Adenomatous Polyposis Treatment Market Facts & Figures by Type
9.3 Central & South America Familial Adenomatous Polyposis Treatment Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Familial Adenomatous Polyposis Treatment by Country
10.1.1 Middle East and Africa Familial Adenomatous Polyposis Treatment Sales by Country
10.1.2 Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Familial Adenomatous Polyposis Treatment Market Facts & Figures by Type
10.3 Middle East and Africa Familial Adenomatous Polyposis Treatment Market Facts & Figures by Application
11 Company Profiles
11.1 Cancer Prevention Pharmaceuticals Inc
11.1.1 Cancer Prevention Pharmaceuticals Inc Corporation Information
11.1.2 Cancer Prevention Pharmaceuticals Inc Description and Business Overview
11.1.3 Cancer Prevention Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Products Offered
11.1.5 Cancer Prevention Pharmaceuticals Inc Related Developments
11.2 Marina Biotech Inc
11.2.1 Marina Biotech Inc Corporation Information
11.2.2 Marina Biotech Inc Description and Business Overview
11.2.3 Marina Biotech Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Marina Biotech Inc Familial Adenomatous Polyposis Treatment Products Offered
11.2.5 Marina Biotech Inc Related Developments
11.3 Thetis Pharmaceuticals LLC
11.3.1 Thetis Pharmaceuticals LLC Corporation Information
11.3.2 Thetis Pharmaceuticals LLC Description and Business Overview
11.3.3 Thetis Pharmaceuticals LLC Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Products Offered
11.3.5 Thetis Pharmaceuticals LLC Related Developments
11.1 Cancer Prevention Pharmaceuticals Inc
11.1.1 Cancer Prevention Pharmaceuticals Inc Corporation Information
11.1.2 Cancer Prevention Pharmaceuticals Inc Description and Business Overview
11.1.3 Cancer Prevention Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Products Offered
11.1.5 Cancer Prevention Pharmaceuticals Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Familial Adenomatous Polyposis Treatment Market Estimates and Projections by Region
12.1.1 Global Familial Adenomatous Polyposis Treatment Sales Forecast by Regions 2021-2026
12.1.2 Global Familial Adenomatous Polyposis Treatment Revenue Forecast by Regions 2021-2026
12.2 North America Familial Adenomatous Polyposis Treatment Market Size Forecast (2021-2026)
12.2.1 North America: Familial Adenomatous Polyposis Treatment Sales Forecast (2021-2026)
12.2.2 North America: Familial Adenomatous Polyposis Treatment Revenue Forecast (2021-2026)
12.2.3 North America: Familial Adenomatous Polyposis Treatment Market Size Forecast by Country (2021-2026)
12.3 Europe Familial Adenomatous Polyposis Treatment Market Size Forecast (2021-2026)
12.3.1 Europe: Familial Adenomatous Polyposis Treatment Sales Forecast (2021-2026)
12.3.2 Europe: Familial Adenomatous Polyposis Treatment Revenue Forecast (2021-2026)
12.3.3 Europe: Familial Adenomatous Polyposis Treatment Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Familial Adenomatous Polyposis Treatment Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Familial Adenomatous Polyposis Treatment Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Familial Adenomatous Polyposis Treatment Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Familial Adenomatous Polyposis Treatment Market Size Forecast by Region (2021-2026)
12.5 Latin America Familial Adenomatous Polyposis Treatment Market Size Forecast (2021-2026)
12.5.1 Latin America: Familial Adenomatous Polyposis Treatment Sales Forecast (2021-2026)
12.5.2 Latin America: Familial Adenomatous Polyposis Treatment Revenue Forecast (2021-2026)
12.5.3 Latin America: Familial Adenomatous Polyposis Treatment Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Familial Adenomatous Polyposis Treatment Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Familial Adenomatous Polyposis Treatment Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Familial Adenomatous Polyposis Treatment Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Familial Adenomatous Polyposis Treatment Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Familial Adenomatous Polyposis Treatment Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Familial Adenomatous Polyposis Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Familial Adenomatous Polyposis Treatment Market Segments
Table 2. Ranking of Global Top Familial Adenomatous Polyposis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Familial Adenomatous Polyposis Treatment Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Icosapent
Table 5. Major Manufacturers of Eflornithine Hydrochloride
Table 6. Major Manufacturers of Aspirin
Table 7. Major Manufacturers of CEQ-508
Table 8. Major Manufacturers of Others
Table 9. Global Familial Adenomatous Polyposis Treatment Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Familial Adenomatous Polyposis Treatment Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Familial Adenomatous Polyposis Treatment Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Regions (2015-2020)
Table 13. Global Familial Adenomatous Polyposis Treatment Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Familial Adenomatous Polyposis Treatment Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Familial Adenomatous Polyposis Treatment Sales Share by Manufacturers (2015-2020)
Table 16. Global Familial Adenomatous Polyposis Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Familial Adenomatous Polyposis Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Familial Adenomatous Polyposis Treatment as of 2019)
Table 18. Familial Adenomatous Polyposis Treatment Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Familial Adenomatous Polyposis Treatment Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Familial Adenomatous Polyposis Treatment Price (2015-2020) (USD/Pcs)
Table 21. Familial Adenomatous Polyposis Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Familial Adenomatous Polyposis Treatment Product Type
Table 23. Date of International Manufacturers Enter into Familial Adenomatous Polyposis Treatment Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 26. Global Familial Adenomatous Polyposis Treatment Sales Share by Type (2015-2020)
Table 27. Global Familial Adenomatous Polyposis Treatment Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Familial Adenomatous Polyposis Treatment Revenue Share by Type (2015-2020)
Table 29. Familial Adenomatous Polyposis Treatment Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 31. Global Familial Adenomatous Polyposis Treatment Sales Share by Application (2015-2020)
Table 32. North America Familial Adenomatous Polyposis Treatment Sales by Country (2015-2020) (K Pcs)
Table 33. North America Familial Adenomatous Polyposis Treatment Sales Market Share by Country (2015-2020)
Table 34. North America Familial Adenomatous Polyposis Treatment Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Familial Adenomatous Polyposis Treatment Revenue Market Share by Country (2015-2020)
Table 36. North America Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 37. North America Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Table 38. North America Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 39. North America Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Table 40. Europe Familial Adenomatous Polyposis Treatment Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Familial Adenomatous Polyposis Treatment Sales Market Share by Country (2015-2020)
Table 42. Europe Familial Adenomatous Polyposis Treatment Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Familial Adenomatous Polyposis Treatment Revenue Market Share by Country (2015-2020)
Table 44. Europe Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Table 46. Europe Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Familial Adenomatous Polyposis Treatment Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Familial Adenomatous Polyposis Treatment Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Familial Adenomatous Polyposis Treatment Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Table 56. Latin America Familial Adenomatous Polyposis Treatment Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Familial Adenomatous Polyposis Treatment Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Familial Adenomatous Polyposis Treatment Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Familial Adenomatous Polyposis Treatment Revenue Market Share by Country (2015-2020)
Table 60. Latin America Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Table 62. Latin America Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Table 72. Cancer Prevention Pharmaceuticals Inc Corporation Information
Table 73. Cancer Prevention Pharmaceuticals Inc Description and Major Businesses
Table 74. Cancer Prevention Pharmaceuticals Inc Familial Adenomatous Polyposis Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Cancer Prevention Pharmaceuticals Inc Product
Table 76. Cancer Prevention Pharmaceuticals Inc Recent Development
Table 77. Marina Biotech Inc Corporation Information
Table 78. Marina Biotech Inc Description and Major Businesses
Table 79. Marina Biotech Inc Familial Adenomatous Polyposis Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Marina Biotech Inc Product
Table 81. Marina Biotech Inc Recent Development
Table 82. Thetis Pharmaceuticals LLC Corporation Information
Table 83. Thetis Pharmaceuticals LLC Description and Major Businesses
Table 84. Thetis Pharmaceuticals LLC Familial Adenomatous Polyposis Treatment Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Thetis Pharmaceuticals LLC Product
Table 86. Thetis Pharmaceuticals LLC Recent Development
Table 87. Global Familial Adenomatous Polyposis Treatment Sales Forecast by Regions (2021-2026) (K Pcs)
Table 88. Global Familial Adenomatous Polyposis Treatment Sales Market Share Forecast by Regions (2021-2026)
Table 89. Global Familial Adenomatous Polyposis Treatment Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 90. Global Familial Adenomatous Polyposis Treatment Revenue Market Share Forecast by Regions (2021-2026)
Table 91. North America: Familial Adenomatous Polyposis Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 92. North America: Familial Adenomatous Polyposis Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 93. Europe: Familial Adenomatous Polyposis Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 94. Europe: Familial Adenomatous Polyposis Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 95. Asia Pacific: Familial Adenomatous Polyposis Treatment Sales Forecast by Region (2021-2026) (K Pcs)
Table 96. Asia Pacific: Familial Adenomatous Polyposis Treatment Revenue Forecast by Region (2021-2026) (US$ Million)
Table 97. Latin America: Familial Adenomatous Polyposis Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 98. Latin America: Familial Adenomatous Polyposis Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 99. Middle East and Africa: Familial Adenomatous Polyposis Treatment Sales Forecast by Country (2021-2026) (K Pcs)
Table 100. Middle East and Africa: Familial Adenomatous Polyposis Treatment Revenue Forecast by Country (2021-2026) (US$ Million)
Table 101. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 102. Key Challenges
Table 103. Market Risks
Table 104. Main Points Interviewed from Key Familial Adenomatous Polyposis Treatment Players
Table 105. Familial Adenomatous Polyposis Treatment Customers List
Table 106. Familial Adenomatous Polyposis Treatment Distributors List
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Familial Adenomatous Polyposis Treatment Product Picture
Figure 2. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Type in 2020 & 2026
Figure 3. Icosapent Product Picture
Figure 4. Eflornithine Hydrochloride Product Picture
Figure 5. Aspirin Product Picture
Figure 6. CEQ-508 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Familial Adenomatous Polyposis Treatment Report Years Considered
Figure 13. Global Familial Adenomatous Polyposis Treatment Market Size 2015-2026 (US$ Million)
Figure 14. Global Familial Adenomatous Polyposis Treatment Sales 2015-2026 (K Pcs)
Figure 15. Global Familial Adenomatous Polyposis Treatment Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Region (2015-2020)
Figure 17. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Region in 2019
Figure 18. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Region (2015-2020)
Figure 19. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Region in 2019
Figure 20. Global Familial Adenomatous Polyposis Treatment Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Familial Adenomatous Polyposis Treatment Revenue in 2019
Figure 22. Familial Adenomatous Polyposis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Type (2015-2020)
Figure 24. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Type in 2019
Figure 25. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Type (2015-2020)
Figure 26. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Type in 2019
Figure 27. Global Familial Adenomatous Polyposis Treatment Market Share by Price Range (2015-2020)
Figure 28. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Application (2015-2020)
Figure 29. Global Familial Adenomatous Polyposis Treatment Sales Market Share by Application in 2019
Figure 30. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Application (2015-2020)
Figure 31. Global Familial Adenomatous Polyposis Treatment Revenue Market Share by Application in 2019
Figure 32. North America Familial Adenomatous Polyposis Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Familial Adenomatous Polyposis Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Familial Adenomatous Polyposis Treatment Sales Market Share by Country in 2019
Figure 35. North America Familial Adenomatous Polyposis Treatment Revenue Market Share by Country in 2019
Figure 36. U.S. Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Familial Adenomatous Polyposis Treatment Market Share by Type in 2019
Figure 41. North America Familial Adenomatous Polyposis Treatment Market Share by Application in 2019
Figure 42. Europe Familial Adenomatous Polyposis Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Familial Adenomatous Polyposis Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Familial Adenomatous Polyposis Treatment Sales Market Share by Country in 2019
Figure 45. Europe Familial Adenomatous Polyposis Treatment Revenue Market Share by Country in 2019
Figure 46. Germany Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Familial Adenomatous Polyposis Treatment Market Share by Type in 2019
Figure 57. Europe Familial Adenomatous Polyposis Treatment Market Share by Application in 2019
Figure 58. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Familial Adenomatous Polyposis Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Market Share by Region in 2019
Figure 61. Asia Pacific Familial Adenomatous Polyposis Treatment Revenue Market Share by Region in 2019
Figure 62. China Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Familial Adenomatous Polyposis Treatment Market Share by Type in 2019
Figure 85. Asia Pacific Familial Adenomatous Polyposis Treatment Market Share by Application in 2019
Figure 86. Latin America Familial Adenomatous Polyposis Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Familial Adenomatous Polyposis Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Familial Adenomatous Polyposis Treatment Sales Market Share by Country in 2019
Figure 89. Latin America Familial Adenomatous Polyposis Treatment Revenue Market Share by Country in 2019
Figure 90. Mexico Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Familial Adenomatous Polyposis Treatment Market Share by Type in 2019
Figure 97. Latin America Familial Adenomatous Polyposis Treatment Market Share by Application in 2019
Figure 98. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue Market Share by Country in 2019
Figure 102. Turkey Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Familial Adenomatous Polyposis Treatment Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Familial Adenomatous Polyposis Treatment Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Familial Adenomatous Polyposis Treatment Market Share by Type in 2019
Figure 109. Middle East and Africa Familial Adenomatous Polyposis Treatment Market Share by Application in 2019
Figure 110. North America Familial Adenomatous Polyposis Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Familial Adenomatous Polyposis Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Familial Adenomatous Polyposis Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Familial Adenomatous Polyposis Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Familial Adenomatous Polyposis Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Familial Adenomatous Polyposis Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Familial Adenomatous Polyposis Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Familial Adenomatous Polyposis Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Familial Adenomatous Polyposis Treatment Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Familial Adenomatous Polyposis Treatment Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
ホモ接合性家族性高コレステロール血症治療の世界市場（～2026年） Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Treatment Market The global Homozygous Familial Hypercholesterolemia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Homozygous Fa…- 鼻ポリポーシス治療薬の世界市場（～2026年） Market Analysis and Insights: Global Nasal Polyposis Drug Market The global Nasal Polyposis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Nasal Polyposis Drug Scope and Market Size Nasal Polyposis Drug market is…
- 家族性アミロイド多発神経障害（FAP）の世界市場（～2026年） Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Globally, development of new dru…
- ヘテロ接合性家族性高コレステロール血症薬の世界市場（～2026年） Market Analysis and Insights: Global Heterozygous Familial Hypercholesterolemia Drug Market The global Heterozygous Familial Hypercholesterolemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Heterozygous Famili…
- 気管支拡張症治療の世界市場（～2026年） Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. This deposition of mucus leads to bacterial infections and hence resulting in serious and repeated lung infections. Bronchiectasis is a long term condition resulting in seri…